Up­dat­ed: FDA ap­proves Sarep­ta’s Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py via ac­cel­er­at­ed path­way

The FDA grant­ed ac­cel­er­at­ed ap­proval to Sarep­ta Ther­a­peu­tics’ Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py for boys aged 4 and 5 in a de­ci­sion that al­lows ac­cess to the first one-time treat­ment for the de­bil­i­tat­ing mus­cle dis­ease.

The gene ther­a­py, known as SRP-9001 or de­landis­tro­gene mox­epar­vovec, will be mar­ket­ed as Ele­v­idys, Sarep­ta an­nounced Thurs­day af­ter­noon. Ele­v­idys will cost $3.2 mil­lion per pa­tient, mak­ing it the sec­ond most ex­pen­sive med­i­cine in the US af­ter CSL Behring and uniQure’s he­mo­phil­ia B gene ther­a­py Hem­genix, which costs $3.5 mil­lion per pa­tient.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER